Drug-drug interactions between androgen receptor signaling inhibitors and direct-acting oral anticoagulants in patients with prostate cancer: Limited agreement between various drug-drug interaction information sources

Resources

Everything you might need. In one page.

Drug-drug interactions between androgen receptor signaling inhibitors and direct-acting oral anticoagulants in patients with prostate cancer: Limited agreement between various drug-drug interaction information sources

Global DDI Solutions

The ASCPT Annual Meeting, recognized as the premier clinical pharmacology event in the U.S., took place in late May, attracting a broad mix of participants. Industry professionals made up the majority (around 70%), followed by academic researchers (20%) and regulatory representatives (10%).

At the meeting, David Burger showcased two important posters focused on drug-drug interaction (DDI) management in prostate cancer and cytomegalovirus (CMV).

The prostate cancer study revealed limited agreement among online interaction checkers regarding DDIs between androgen receptor inhibitors and DOACs, raising concerns for prostate cancer care.

You can fin the poster on CMV here